PARAGON-II is a Phase II, non-randomised, open-label, basket study aiming to evaluate the activity and tolerability of combination aromatase inhibitor with a CDK4/6 inhibitor or PIK3CA inhibitor in post-menopausal patients with advanced (recurrent/metastatic) hormone-receptor positive (HR+) gynaecological cancers.

Supported By:

Eligibility:

Patients with histologically proven recurrent/metastatic, HR+, cancers of the ovaries, fallopian tubes, or peritoneum (including high-grade and low-grade serous cancers), granulosa cell ovarian cancers and endometrial cancer (including epithelial cancers and sarcomas).

Registration ID:

Participation:

Australia and New Zealand

Australian Lead Group:

Australia New Zealand Gynaecological Oncology Group (ANZGOG)

Status:

Recruiting

Activation Date:

31.05.2022

Chairs:

A/Prof Chee Lee and Prof Michael Friedlander

Contact:

paragon2.study@sydney.edu.au